Skip to content

Carbon Dioxide Laser vs. Electrocoagulation for the Therapy of Condyloma

Carbon Dioxide Laser Ablation Versus Electrocoagulation - a Prospective, Randomized Single-center Trial Comparing Two Surgical Treatments in Women Undergoing Therapy for Condyloma Acuminata

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02520986
Enrollment
140
Registered
2015-08-13
Start date
2016-10-25
Completion date
2026-01-19
Last updated
2026-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condylomata Acuminata

Keywords

Sexually transmitted disease, Genital Warts, Venereal Warts

Brief summary

In a randomized clinical trial of 114 women undergoing Treatment for condyloma acuminata, two surgical methods, the carbon dioxide laser Ablation and the excision by electrocoagulation, will be compared. The primary outcome of the study is the cosmetic result judged by the Patient 6 weeks after Treatment using a 11-step numerical rating scale (NRS), secondary outcomes are intervention time, operative complications, subjects and users satisfaction, postoperative pain and recurrence of genital warts.

Interventions

DEVICECarbon dioxide Laser ablation

surgical Instrument to achieve excision of genital warts by a pulsed laser of 15 Watt voltage - NOTE: pulsed 15 W was never used; the actual setting was 5W continuous

surgical Instrument to achieve excision of genital warts by a deep tissue electrocoagulation of 80 Watt voltage

Sponsors

Ruhr University of Bochum
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* informed consent * women with anogenital affection of condyloma acuminata

Exclusion criteria

* significant language barrier * pregnancy * unwillingness to participate * the use of blood thinner or known coagulation disorder * the use of immunosuppressive medicament * HIV-Infection * malignant diseases * local therapy within 8 weeks before Treatment * wound healing disorder

Design outcomes

Primary

MeasureTime frameDescription
Cosmetic result6 weeksCosmetic result judged by the Patient 6 weeks after Treatment using a 11-step numerical rating scale (NRS)

Secondary

MeasureTime frameDescription
users satisfaction30 minutessurgeons will score their satisfaction concerning the used technique by using a 11-step numerical rating scale (NRS) within 30 minutes after surgery
Operation time20 minutesthe time from the beginning of the Treatment until the end of the operation (the end of hemostatic interventions) will be measured in minutes
Postoperative pain5 hourspatients will score their postoperative pain Level using a 11-step numerical rating scale (NRS) within 5 hours after surgery
Subjects satisfaction6 weeksPatients will score their Overall satisfaction by using a 11-step numerical rating scale (NRS) 6 weeks after Treatment
Recurrence of genital warts12 weeksan examination will be performed 12 weeks after surgery; Recurrence of genital warts will be determined if one or more Areas are infected by genital warts
Operative complications14 daysOperative complications defined as necessity to intervene surgically up to 14 days postoperatively (number of patients with operative complications and type of complication)
Cosmetic result12 weeksCosmetic result judged by the Patient 12 weeks after Treatment using a 11-step numerical rating scale (NRS)

Countries

Germany

Contacts

PRINCIPAL_INVESTIGATORClemens Tempfer, Dr. med.

Marien Hospital Herne, Klinikum der Ruhr-Universität Bochum

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 16, 2026